HomeCompareHJLI vs SPHD

HJLI vs SPHD: Dividend Comparison 2026

HJLI yields 19.27% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HJLI wins by $43.3K in total portfolio value
10 years
HJLI
HJLI
● Live price
19.27%
Share price
$10.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.8K
Annual income
$6,227.54
Full HJLI calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — HJLI vs SPHD

📍 HJLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHJLISPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HJLI + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HJLI pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HJLI
Annual income on $10K today (after 15% tax)
$1,637.76/yr
After 10yr DRIP, annual income (after tax)
$5,293.41/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, HJLI beats the other by $4,811.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HJLI + SPHD for your $10,000?

HJLI: 50%SPHD: 50%
100% SPHD50/50100% HJLI
Portfolio after 10yr
$48.2K
Annual income
$3,397.45/yr
Blended yield
7.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HJLI right now

HJLI
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
14.9
Piotroski
3/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HJLI buys
0
SPHD buys
0
No recent congressional trades found for HJLI or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHJLISPHD
Forward yield19.27%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$69.8K$26.5K
Annual income after 10y$6,227.54$567.37
Total dividends collected$38.9K$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HJLI vs SPHD ($10,000, DRIP)

YearHJLI PortfolioHJLI Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$12,627$1,926.78$11,130$430.50+$1.5KHJLI
2$15,784$2,273.74$12,357$447.82+$3.4KHJLI
3$19,546$2,656.40$13,687$464.65+$5.9KHJLI
4$23,988$3,074.20$15,126$480.98+$8.9KHJLI
5$29,193$3,526.09$16,682$496.78+$12.5KHJLI
6$35,247$4,010.50$18,362$512.03+$16.9KHJLI
7$42,240$4,525.40$20,174$526.72+$22.1KHJLI
8$50,265$5,068.41$22,127$540.84+$28.1KHJLI
9$59,421$5,636.78$24,230$554.39+$35.2KHJLI
10$69,808$6,227.54$26,493$567.37+$43.3KHJLI

HJLI vs SPHD: Complete Analysis 2026

HJLIStock

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

Full HJLI Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this HJLI vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HJLI vs SCHDHJLI vs JEPIHJLI vs OHJLI vs KOHJLI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.